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Abstract Advanced glycation end products (AGE) are known to
serve as ligands for the scavenger receptors such as SR-A, CD36
and SR-BI. In the current study, we examined whether AGE is
recognized by lectin-like oxidized low density lipoprotein
receptor-1 (LOX-1). Cellular binding experiments revealed that
AGE-bovine serum albumin (AGE-BSA) showed the specific
binding to CHO cells overexpressing bovine LOX-1 (BLOX-1),
which was effectively suppressed by an anti-BLOX-1 antibody.
Cultured bovine aortic endothelial cells also showed the specific
binding for AGE-BSA, which was suppressed by 67% by the anti-
BLOX-1 antibody. Thus, LOX-1 is identified as a novel
endothelial receptor for AGE. ß 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
In the Maillard reaction, incubation of proteins with glu-
cose leads, through the formation of early products such as
Schi¡ base and Amadori products, to formation of advanced
glycation end products (AGE) [1,2]. During AGE formation,
several aldehydes such as 3-deoxyglucosone [3], glycolalde-
hyde [4], glyoxal [4] and methylglyoxal (MG) [3] are generated
as intermediates and react mainly with lysine and arginine
residues of proteins. Through modi¢cation of these basic ami-
no acids, proteins lose positive charges and increase their net
negative charges [4]. AGE proteins are characterized physico-
chemically by £uorescence, browning, molecular cross-linking
[1,2] and biologically by ligands speci¢cally recognized by
AGE receptors [5^13]. Accumulation of AGE in human tis-
sues is thought to increase with aging and age-related disor-
ders such as diabetic complications and atherosclerosis [14^
19]. AGE receptors so far identi¢ed are the receptor for AGE
(RAGE) [5], a complex of OST-48/80K-H/galectin-3 [6,7,10],
class A scavenger receptor (SR-A) [8,9], CD36 [12] and SR-BI
(a class B scavenger receptor) [13]. AGE ligands bound to SR-
A [8], CD36 [12] and SR-BI [13] are known to undergo endo-
cytic uptake and subsequent lysosomal degradation [8]. It is
also known that the binding of AGE ligands to RAGE gen-
erates intracellular signals that lead to induction of several
genes such as vascular cell adhesion molecule-1 [20] and tissue
factor [21].
Lectin-like oxidized low density lipoprotein receptor-1
(LOX-1) is identi¢ed as a novel scavenger receptor for oxi-
dized low density lipoprotein (Ox-LDL) which is highly ex-
pressed on endothelial cells [22]. LOX-1 mediates endocytic
uptake and subsequent lysosomal degradation of Ox-LDL. In
addition to Ox-LDL, LOX-1 recognizes aged/apoptotic cells
[23], activated platelets [24] and bacteria [25] as ligands. Bind-
ing of Ox-LDL to LOX-1 induces several cellular events in
endothelial cells such as activation of NF-UB [26], up-regula-
tion of monocyte chemoattractant protein-1 [27], and reduc-
tion in intracellular nitric oxide [28], which may play as a
trigger for onset of cardiovascular events or an accelerator
in the development of atherosclerosis.
Since the binding of various ligands to LOX-1 is sensitively
inhibited by polyanionic compounds like polyinocinic acid
[23,29], negative charge of a ligand is likely to be an essential
factor for its binding to LOX-1. AGE proteins are also neg-
atively charged and their binding to mouse macrophage-de-
rived Raw 264.7 cells [4] and rabbit smooth muscle cells [11] is
e¡ectively inhibited by polyanionic compounds. Moreover,
LOX-1 is a member of the scavenger receptor family to which
the AGE receptors such as SR-A [8,9], CD36 [12] and SR-BI
[13] belong. Thus, we speculated that AGE-modi¢ed proteins
might behave as ligands for LOX-1 as well as Ox-LDL. To
test this hypothesis, we examined the interaction of AGE pro-
teins with LOX-1. The results showed that AGE behaves as a
novel ligand for LOX-1.
2. Materials and methods
2.1. Preparation of AGE-BSA and aldehyde-modi¢ed proteins
AGE-bovine serum albumin (AGE-BSA) was prepared as described
previously [30]. Brie£y, 2.0 g of BSA was incubated with 3.0 g of D-
glucose in 10 ml of 0.5 M sodium phosphate bu¡er (pH 7.4) for 40
weeks at 37‡C, and dialyzed against phosphate-bu¡ered saline (PBS).
The extent of lysine modi¢cation in AGE-BSA was 75.7% of total
lysine residues when determined by amino acid analysis after acid
hydrolysis [4]. BSA (2 mg/ml) was incubated for 14 days at 37‡C
with 33 mM MG (Sigma, St. Louis, MO, USA), glycolaldehyde (Sig-
ma) or 3-deoxyglucosone prepared as described previously [31] in 100
mM sodium phosphate bu¡er (pH 7.4), followed by dialysis against
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PBS [4]. AGE-BSA was labeled with 125I by using Iodogen (Pierce
Chemical Co.) to a speci¢c radioactivity of 850 cpm/ng.
2.2. Lipoprotein preparation
LDL (d = 1.019^1.063 g/ml) was isolated by sequential ultracentri-
fugation of fresh plasma from normolipidemic subjects after overnight
fasting [32]. Ox-LDL was prepared by incubating LDL (0.1 mg/ml)
for 16 h at 37‡C with 5 WM CuSO4, followed by addition of 1 mM
EDTA and cooling [32]. Ox-LDL was labeled with 125I by the method
of McFarlane [33] to a speci¢c radioactivity of 510 cpm/ng.
2.3. Cell culture
CHO cells overexpressing bovine LOX-1 (BLOX-1-CHO) were se-
lected after stable transfection of CHO cells with BLOX-1 as de-
scribed previously [22]. Cells were maintained with Ham’s F-12 me-
dium (Gibco) supplemented with 10 Wg/ml of blasticidin S
(Funakoshi, Tokyo, Japan) and 10% fetal calf serum (FCS) in a
humidi¢ed air with 5% CO2 [22]. Bovine aortic endothelial cells
(BAEC) were isolated by scraping the inner surface of bovine aorta
and cultured with Dulbecco’s modi¢ed Eagle’s medium (DMEM)
containing 10% FCS [22]. BLOX-1-CHO cells (4U104/well) or
BAEC (8U104/well) were seeded to 24-well plates (15 mm in diame-
ter) and further grown with each medium for 2 days and subjected to
cellular assays as described below.
2.4. Cellular assays
For endocytic degradation assays, BLOX-1-CHO cells grown in 24-
well plates were incubated for 6 h at 37‡C in 1.0 ml of DMEM
containing 3% BSA (medium A) with various concentrations of
[125I]AGE-BSA or [125I]Ox-LDL in the presence or absence of excess
amounts of unlabeled ligands. An aliquot (0.75 ml) of the culture
medium was mixed with 0.3 ml of 40% trichloroacetic acid (TCA).
To this solution was added 0.2 ml of 0.7 M AgNO3, followed by
centrifugation at 2500Ug for 10 min. TCA-soluble radioactivity in
the supernatant (0.5 ml) was measured for determination of endocytic
degradation [8]. The remaining cells were washed twice with 1 ml of
PBS containing l% BSA and then twice with 1 ml of PBS. The cells
were solubilized with 0.5 ml of 0.1 N NaOH and the cell-associated
radioactivity and cell proteins were determined [8,34]. For binding
assays, BLOX-1-CHO cells or BAEC in 1.0 ml of medium A were
incubated for 90 min at 4‡C with various concentrations of [125I]AGE-
BSA or [125I]Ox-LDL in the presence or absence of excess amounts of
unlabeled ligands or in the indicated amount of the anti-BLOX-1
antibody [22] or control IgG. Each well was washed twice with ice-
cold PBS containing 1% BSA and then twice with ice-cold PBS, fol-
lowed by determination of cell-bound radioactivity as described pre-
viously [11]. The anti-BLOX-1 antibody was prepared in mice as
described previously [22].
3. Results
3.1. Interaction of AGE with BLOX-1-CHO cells
Binding assays at 4‡C showed speci¢c and saturable binding
of [125I]Ox-LDL to BLOX-1-CHO cells with an apparent Kd
of 6.6 Wg/ml and maximal binding of 339 ng/mg cell protein
(Fig. 1A), indicating expression of a signi¢cant amount of
BLOX-1 by these cells. [125I]AGE-BSA binds to these
BLOX-1-CHO cells in a speci¢c and saturable manner and
the Scatchard analysis revealed a single binding site for
AGE-BSA with an apparent Kd of 9.8 Wg/ml and maximal
binding of 47.5 ng/mg cell protein (Fig. 1B), indicating that
AGE-BSA serves as a ligand for LOX-1. Upon incubation at
37‡C, cell-association of [125I]AGE-BSA with BLOX-1-CHO
cells increased in a dose-dependent manner, whereas the
mock-transfected CHO cells did not show any signi¢cant
cell-association (Fig. 2A). In contrast to Ox-LDL, however,
subsequent endocytic degradation of [125I]AGE-BSA by
BLOX-1-CHO cells did not occur at an appreciable level
(Fig. 2B), suggesting that AGE-BSA binds to LOX-1 but fails
to undergo endocytic degradation in BLOX-1-CHO cells.
3.2. Cross-competition between AGE-BSA and Ox-LDL
Competitive binding assays were performed to further char-
acterize the binding of AGE ligands to LOX-1. Cellular bind-
ing of [125I]AGE-BSA was e¡ectively (more than 80%) com-
peted for by unlabeled AGE-BSA and Ox-LDL. In addition
to AGE-BSA, we examined whether BSA modi¢ed by MG,
glycolaldehyde or 3-deoxyglucosone, intermediate aldehydes
generated during the Maillard reaction [3,4], could serve as
AGE ligands. E¡ects of MG-modi¢ed BSA (MG-BSA) and
glycolaldehyde-modi¢ed BSA (GA-BSA) on the cellular bind-
ing of AGE-BSA to BLOX-1-CHO cells were as inhibitory as
unlabeled AGE-BSA and Ox-LDL, whereas 3-deoxygluco-
sone-modi¢ed BSA had no such an inhibitory e¡ect (Fig.
3A). Under the parallel conditions, the binding of [125I]Ox-
LDL to these cells was signi¢cantly inhibited by unlabeled
Ox-LDL, but inhibitory e¡ects of other ligands tested were
partial (Fig. 3B). Under these binding conditions, the cellular
binding of AGE-BSA and Ox-LDL was signi¢cantly inhibited
by the anti-BLOX-1 antibody (60 and 70%, respectively),
whereas non-immune IgG had no e¡ect at all (Fig. 3A,B).
Fig. 1. Cellular binding of [125I]Ox-LDL (A) and [125I]AGE-BSA
(B) to BLOX-1-CHO cells. BLOX-1-CHO cells were incubated for
90 min at 4‡C with the indicated concentrations of [125I]Ox-LDL
(A) or [125I]AGE-BSA (B) in the absence (open circle) or presence
(open triangle) of 0.5 mg/ml unlabeled Ox-LDL (A) or AGE-BSA
(B), followed by determination of the cell-bound radioactivity. Spe-
ci¢c binding (close circle) was determined by subtracting non-specif-
ic binding (open triangle) from total binding (open circle). Insets,
Scatchard analyses of the speci¢c binding curves. Data are represen-
tatives of three separate experiments with duplicate wells.
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3.3. LOX-1 as an endothelial AGE receptor
Since LOX-1 was reported to be highly expressed by endo-
thelial cells, we determine whether LOX-1 could also serve as
the AGE receptor on endothelial cells. The binding of
[125I]AGE-BSA to cultured BAEC was competitively inhibited
by 75% by unlabeled AGE-BSA (Fig. 4) and by 50% by the
anti-BLOX-1 antibody (corresponding to two-thirds of the
speci¢c binding), whereas non-immune IgG had no e¡ect, in-
dicating that a substantial part of the speci¢c binding of
[125I]AGE-BSA to these endothelial cells is mediated by
LOX-1.
4. Discussion
We previously demonstrated that AGE-modi¢ed proteins
serve as ligands for the scavenger receptors such as SR-A
[8,9], CD36 [12] and SR-BI [13]. As an extension of these
studies, we examined whether AGE ligands could serve as
ligands for LOX-1, another scavenger receptor for Ox-LDL
[22]. The results clearly showed high a⁄nity binding of AGE-
BSA to BLOX-1-CHO cells (Fig. 1B), which was e¡ectively
suppressed by the anti-BLOX-1 antibody (Fig. 3A), indicating
that AGE ligands are recognized as ligands by LOX-1.
Among ligands tested, MG-BSA and GA-BSA behaved as
e¡ective ligands as AGE-BSA (Fig. 3A). MG-BSA is known
to undergo receptor-mediated endocytosis by murine P388D1
macrophages [35]. Since LOX-1 is expressed in mouse exudate
peritoneal macrophages [36], LOX-1 might be a receptor in
P388D1 macrophages responsible for endocytosis of MG-
BSA. Similarly, GA-BSA but not MG-BSA, is recognized
by SR-A as an active ligand [4]. Although protein modi¢ca-
tion by MG or glycolaldehyde is known to generate several
structures such as NO-(carboxyethyl)lysine [37], imidazolone
[38] and some other AGE-structures, the key structure critical
for the interaction with LOX-1 has to be determined by future
Fig. 2. Endocytic uptake of [125I]AGE-BSA or [125I]Ox-LDL by
BLOX-1-CHO cells. A: BLOX-1-CHO cells or mock-CHO cells
were incubated for 6 h at 37‡C with the indicated concentrations of
[125I]AGE-BSA in the absence or presence of 0.5 mg/ml unlabeled
AGE-BSA, followed by determination of the cell-associated [125I]-
AGE-BSA. Speci¢c cell-association was determined by subtracting
non-speci¢c cell-association from total cell-association. B: BLOX-1-
CHO cells were incubated for 6 h at 37‡C with the indicated con-
centrations of [125I]AGE-BSA or [125I]Ox-LDL in the absence or
presence of 0.5 mg/ml of unlabeled AGE-BSA or Ox-LDL, respec-
tively. TCA-soluble radioactivity in the supernatant was measured
for determination of endocytic degradation of each ligand. Speci¢c
degradation was determined by subtracting non-speci¢c degradation
from total degradation. Data are representatives of three separate
experiments with duplicate wells.
Fig. 3. Cross-competition between Ox-LDL and AGE-BSA. BLOX-
1-CHO cells were incubated for 90 min at 4‡C with 5 Wg/ml of
[125I]AGE-BSA (A) or [125I]Ox-LDL (B) in the absence or presence
of 0.25 mg/ml of unlabeled ligands, 30 Wg/ml of anti-BLOX-1 anti-
body, or 30 Wg/ml of non-immune IgG. After the incubation, the
cell-bound radioactivity was determined. Data are representatives of
three separate experiments with duplicate wells.
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studies. In this connection, NO-(carboxymethyl)lysine was re-
ported to serve as a ligand for RAGE [39].
The binding of Ox-LDL and AGE-BSA to BLOX-1-CHO
cells is characterized by non-reciprocal cross-competition (Fig.
3) as previously reported in SR-A [40]. Recently, SR-BI, a
receptor that binds to high density lipoproteins (HDL) and
mediates selective uptake of HDL cholesteryl ester [41], was
also demonstrated to serve as the AGE receptor [13]. Cross-
competition experiments between AGE-BSA and HDL
showed that binding of AGE-BSA or that of HDL to CHO
cells overexpressing SR-BI (CHO-SR-BI) was not a¡ected by
the other ligand. One possible explanation for such non-recip-
rocal cross-competition is the presence of multiple ligand
binding sites on SR-BI and LOX-1. To test this notion, site-
directed mutagenesis of each scavenger receptor will be useful.
It is also interesting that fates of Ox-LDL and AGE-BSA
after binding to LOX-1 are distinct to each other; endocytic
degradation occurs to Ox-LDL but not to AGE-BSA (Fig.
2B). Di¡erential processing of the ligands was also observed
in CHO-SR-BI cells ; AGE-BSA but not HDL undergoes en-
docytic degradation after binding to SR-BI [13]. Further stud-
ies are needed to elucidate the possible relationship between
the speci¢c ligand binding sites on the scavenger receptors and
di¡erential intracellular sorting of the ligands.
The most important physiological implication of this study
is that a substantial part of the speci¢c binding of AGE-BSA
to BAEC is mediated by LOX-1 (Fig. 4), indicating that
LOX-1 might contribute to a major AGE receptor expressed
on primary endothelial cells. It is generally accepted that
RAGE is a representative AGE receptor in endothelial cells
[5,20]. Intraperitoneal administration of a soluble form of
RAGE (sRAGE) signi¢cantly suppressed atherosclerotic le-
sions accelerated under streptozotocin-induced diabetic condi-
tions in apolipoprotein E-knockout mice [42]. The unique
anti-atherogenic e¡ect of sRAGE was explained by trapping
plasma or tissue AGE ligands by sRAGE, thus inhibiting the
interaction between AGE and RAGE. In this connection, the
present study clearly showed that LOX-1 serves as another
endothelial receptor for AGE ligands. It seems reasonable to
assume that by forming a complex with AGE ligands, sRAGE
could block AGE^LOX-1 interaction in addition to AGE^
RAGE interaction. Therefore, the anti-atherogenic e¡ect of
sRAGE could be due, in part, to blockade of LOX-1 function.
To get further insight into this issue, it is important to know
whether the interaction of AGE ligands with LOX-1 could
induce the cellular events that were reported to occur with
the interaction of Ox-LDL with LOX-1 [26^28].
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